Pharma Pulse 7/16/25: LEAP-002 Study Shows Five Year Survival Consistency in Unresectable Liver Cancer; Building Clinical Trial Infrastructure Inside Pharmacies

LEAP-002 Study Shows Five Year Survival Consistency in Unresectable Liver Cancer

In an interview with Pharmaceutical Executive, Corina Dutcus, SVP at Eisai, discussed nearly five-year follow-up data from the LEAP-002 study, which—despite missing its primary endpoint—reinforced lenvatinib’s durability and safety as a first-line treatment for unresectable liver cancer, while also highlighting Eisai’s continued oncology pipeline progress in hepatocellular and endometrial carcinomas.

Building Clinical Trial Infrastructure Inside Pharmacies

In an interview with Applied Clinical Trials, Ramita Tandon, chief biopharma officer at Walgreens, discussed how the company is leveraging its nationwide pharmacy footprint, trusted community relationships, and patient insights to build clinical trial infrastructure that improves access, boosts diversity, and redefines trials as a care option for underserved populations.

Finerenone and the Future of Diabetes-Related Kidney Care

Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has emerged as a promising treatment for patients with chronic kidney disease and type 2 diabetes, demonstrating significant reductions in kidney disease progression and cardiovascular events across multiple large trials, while offering a more favorable safety profile compared to traditional therapies.

Q&A: Pharmacists Play Essential Role in Insulin Therapy Success

In an interview with Drug Topics, Jennifer Clements, PharmD, emphasized the essential role pharmacists play in supporting insulin therapy by educating patients on insulin types, addressing cost and stigma, easing injection anxiety, and using personalized strategies to improve adherence and empower long-term diabetes self-management.

China Biotechs ‘Reshaping’ US Biopharma as Outlicensing Deals Rise 11%: Jefferies Report

International biopharma companies are increasingly turning to Chinese biotechs for licensing deals—now accounting for nearly a third of outlicensing value—driven by mounting pressures from drug pricing and patent expirations, as China’s rapidly growing biotech sector offers credible, cost-effective, and fast-to-market assets that are reshaping the U.S. biopharma landscape.